Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Conditions
Interventions
PRS-343
Locations
10
United States
University of Arizona Cancer Center
Tucson, Arizona, United States
University of California Los Angeles (UCLA)
Santa Monica, California, United States
Georgetown University, Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania, United States
Start Date
September 13, 2017
Primary Completion Date
December 1, 2023
Completion Date
December 1, 2023
Last Updated
April 22, 2024
NCT06253871
NCT04886531
NCT04585750
NCT07459673
NCT07102381
NCT07053085
Lead Sponsor
Pieris Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions